Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Sogo Medical to Increase Number of Mentaio Pharmacies to 20 in 3 Years
July 11, 2011
- DPJ Lawmakers Call for Withdrawal of Proposal to Unify Basic Dispensing Fees
July 11, 2011
- DPJ's Diet Members Adopt Opinion Paper Calling for Deregulating Online Sales of OTC Drugs
July 11, 2011
- Mediceo to Use Its MR-Certified MSs to Promote Orphan Drugs
July 11, 2011
- Ono, Evotec Succeed in Discovering Lead Compounds in Iron Channel Drug Discovery
July 11, 2011
- Eisai to Enhance Liver Disease Franchise in Asia/Pacific Region
July 11, 2011
- Pfizer Remains Top Global Drug Maker; Mergers Shake up Ranking
July 11, 2011
- Sanofi-aventis, Tohoku Univ. Sign Comprehensive Agreement for Life Science Research
July 11, 2011
- 24 APIs/34 Products Approved Following New Procedures
July 11, 2011
- Kyowa Hakko Kirin Starts Domestic PIII Trial for KW-3357
July 11, 2011
- Approvals for 3 Dasen-Like Drugs to Be Withdrawn
July 11, 2011
- AnGes MG Obtains Substance Patent for Novel Peptide AG-30 in Japan
July 11, 2011
- METI's Council Proposes Review of Patients' Drug Copayments
July 11, 2011
- Sawai May Embark on Follow-on Antibody Drugs in Mid-2010s: President Sawai
July 11, 2011
- AnGes MG Obtains Patent on HVJ-E for Cancer
July 4, 2011
- R&I Upgrades Kaken's Rating from “Stable”to “Positive”
July 4, 2011
- Takeda Applies for SGN-35 in Europe
July 4, 2011
- Current Users to Be Permitted to Rely on Telemarketing to Buy Reclassified Class 2 OTC Drugs
July 4, 2011
- R&I Keeps AA- Rating for Eisai
July 4, 2011
- Merck Serono Stops Global Approval Process for Cladribine
July 4, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…